ICTI Biostatistics Expert speaks at International Conference

January 24, 2006

Yardley, PA – January 24, 2006 – Continuing Interactive Clinical Technologies Inc.’s (ICTI) leadership in Adaptive Clinical Trial Design and Implementation, ICTI’s Associate Director of Biostatistics, Eva Miller, Ph.D., has been invited to present at the upcoming Strategic Management Information (SMi) meeting of Innovating Clinical Drug Development. The annual conference, being held January 25-26, 2006 in London, includes a session in which Dr. Miller will present on,

“Customized Software Incorporating Adaptive Randomizations for Clinical Trials.”

Because of the efficiencies they allow, adaptive trial designs are increasingly being used by both small biotechs and large pharmaceutical companies. Adaptive randomizations, a type of adaptive trial design, are especially valuable for large studies with many subpopulations or when blinding of study drug/device versus placebo is not possible. They are often used in studies of rare diseases, in oncology studies, and in medical device trials. Dr. Miller’s presentation will recount ICTI’s experience in working with clients to design and execute adaptive clinical trial designs.

Richard McCann, ICTI’s President, noted,

“Our unique combination of technologies for real-time clinical trial data capture, along with the capabilities of our sister company Clinical Trial Services (CTS) to provide state-of-the-art clinical supplies management, positions ICTI to make adaptive clinical trial designs feasible. We are delighted to have our capabilities and experience presented at this prestigious conference.”

About ICTI and Almac Sciences

ICTI has been implementing adaptive randomization designs since 1999, and its technologies and services have been used in over 60 adaptive randomization studies. ICTI is a division of Almac Sciences that specializes in interactive solutions to accelerate the clinical trials process and reduce the costs of clinical trials. Our solutions include Interactive Voice Response (iVR) for patient randomization, dosing and clinical supply management; iDiary phone-based patient diaries; iTrial EDC for clinical trials data; and forecasting for clinical trials supplies planning.

Almac Sciences and its affiliated companies (CSS (Chemical Synthesis Services), CTS (Clinical Trial Services), ICTI (Interactive Clinical Technologies Incorporated), PDMS (Pharmaceutical Development and Manufacturing Services) and Almac Diagnostic Services) provide a broad range of services across drug discovery, diagnostics, pharmaceutical research and development, manufacture of API, clinical trials and drug product manufacture. US operations are based in Pennsylvania, North Carolina and California. European operations are headquartered in Craigavon, Northern Ireland with additional operations in London and Edinburgh.

Contact Jim Murphy or Meghan Adams US: 267-685-4284 / info@icti-almac.com

Share

Back to news